Javascript must be enabled to continue!
A syntenin-deficient microenvironment educates AML for aggressiveness
View through CrossRef
Abstract
In acute myeloid leukemia (AML), the stromal microenvironment plays a prominent role in promoting tumor cell survival and progression. Although widely explored, the crosstalk between leukemic and stromal cells remains poorly understood. Syntenin, a multi-domain PDZ protein, controls both the trafficking and signaling of key molecules involved in intercellular communication. Therefore, we aimed to clarify the role of environmental syntenin in the progression of AML. By
in vivo
approaches in syngeneic mice, we demonstrate that a syntenin-deficient environment reprograms AML blasts to survive independently of the stroma. Up-regulation of EEF1A2 in the blasts controls this gain of cell survival. Furthermore, using
ex vivo
co-culture systems, we show that syntenin-deficient bone marrow stromal cells (BMSC) enhance the survival of different types of AML cells, including patient samples, and suffice to educate syngeneic AML, recapitulating micro-environmental effects observed
in vivo.
We establish that syntenin-deficiency causes an increase of eIF5A and autophagy-related factors in BMSC, and provide evidence that the inhibition of autophagy prevents syntenin-deficient BMSC to stimulate AML survival. Altogether, these findings indicate that host-syntenin in the BM microenvironment acts as a repressor of AML aggressiveness.
Key points
-
A syntenin-deficient host reprograms AML blasts, enhancing total protein synthesis and cell survival pathways
-
Autophagy in the syntenin-deficient microenvironment is responsible for the gain of AML cell survival
Title: A syntenin-deficient microenvironment educates AML for aggressiveness
Description:
Abstract
In acute myeloid leukemia (AML), the stromal microenvironment plays a prominent role in promoting tumor cell survival and progression.
Although widely explored, the crosstalk between leukemic and stromal cells remains poorly understood.
Syntenin, a multi-domain PDZ protein, controls both the trafficking and signaling of key molecules involved in intercellular communication.
Therefore, we aimed to clarify the role of environmental syntenin in the progression of AML.
By
in vivo
approaches in syngeneic mice, we demonstrate that a syntenin-deficient environment reprograms AML blasts to survive independently of the stroma.
Up-regulation of EEF1A2 in the blasts controls this gain of cell survival.
Furthermore, using
ex vivo
co-culture systems, we show that syntenin-deficient bone marrow stromal cells (BMSC) enhance the survival of different types of AML cells, including patient samples, and suffice to educate syngeneic AML, recapitulating micro-environmental effects observed
in vivo.
We establish that syntenin-deficiency causes an increase of eIF5A and autophagy-related factors in BMSC, and provide evidence that the inhibition of autophagy prevents syntenin-deficient BMSC to stimulate AML survival.
Altogether, these findings indicate that host-syntenin in the BM microenvironment acts as a repressor of AML aggressiveness.
Key points
-
A syntenin-deficient host reprograms AML blasts, enhancing total protein synthesis and cell survival pathways
-
Autophagy in the syntenin-deficient microenvironment is responsible for the gain of AML cell survival.
Related Results
Comprehensive Investigation of 225 Patients with Myeloid Malignancies and Erythroid Hyperplasia (≥50%) Demonstrates That Acute Erythroid Leukemia (AEL, according WHO Classification 2008) Differs Significantly From MDS but Overlaps with Other AML Subtypes
Comprehensive Investigation of 225 Patients with Myeloid Malignancies and Erythroid Hyperplasia (≥50%) Demonstrates That Acute Erythroid Leukemia (AEL, according WHO Classification 2008) Differs Significantly From MDS but Overlaps with Other AML Subtypes
Abstract
Abstract 1672
Introduction:
According to the WHO 2008, acute erythroid leukemia (AEL) is defined by eryt...
Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML
Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML
Abstract
Introduction:
Patients exposed to cytotoxic agents are at a higher risk of developing therapy related AML and MDS (tAML/tMDS), and have poor ...
Venous-Thromboembolism in Elderly Patients with Acute Myeloid Leukemia
Venous-Thromboembolism in Elderly Patients with Acute Myeloid Leukemia
BACKGROUND: Venous-thromboembolism (VTE) is a debilitating condition and is associated with excess mortality. Small, single institution studies suggest that the risk of VTE in acut...
Downregulation of stromal syntenin sustains AML development
Downregulation of stromal syntenin sustains AML development
Abstract
The crosstalk between cancer and stromal cells plays a critical role in tumor progression. Syntenin is a small scaffold protein involved...
Downregulation of stromal syntenin sustains AML development
Downregulation of stromal syntenin sustains AML development
Abstract
The crosstalk between cancer and stromal cells plays a critical role in tumor progression. Syntenin is a small scaffold protein invo...
Bi-allelic TET2 alterations are frequently found in NPM1 mutated AML and constitute a distinct subgroup with unfavorable prognosis
Bi-allelic TET2 alterations are frequently found in NPM1 mutated AML and constitute a distinct subgroup with unfavorable prognosis
Abstract
Background: Mutations (mut) in TET2 and NPM1 are common in myeloid neoplasms, with NPM1mut defining a distinct ...
Secondary acute myeloid leukemia and de novo acute myeloid leukemia with myelodysplasia-related changes - close or complete strangers?
Secondary acute myeloid leukemia and de novo acute myeloid leukemia with myelodysplasia-related changes - close or complete strangers?
Aim: To compare the main features of patients with secondary acute myeloid leukemias (AMLs) after post-myelodysplastic syndrome (AML-post-MDS) or post-myeloproliferative neoplasms ...
Abstract 5120: Surveying the AML surfaceome for novel immunotherapeutic targets
Abstract 5120: Surveying the AML surfaceome for novel immunotherapeutic targets
Abstract
Acute myeloid leukemia (AML) therapy requires very intensive chemotherapy/stem cell transplant that cures only 60% of children and 25% of adults with AML. T...

